Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research
Pharmaceutics,
Год журнала:
2025,
Номер
17(1), С. 56 - 56
Опубликована: Янв. 3, 2025
Psoriasis,
a
chronic
inflammatory
dermatosis,
represents
significant
clinical
challenge
due
to
its
complex
pathogenesis
and
the
limitations
of
existing
therapeutic
strategies.
Current
psoriasis
diagnoses
are
primarily
clinician-dependent,
with
instrumental
diagnostics
serving
as
adjuncts.
Ongoing
research
is
progressively
deciphering
molecular
underpinnings;
future
may
involve
genetic
immunological
profiling
pinpoint
biomarkers,
enabling
more
accurate
timely
interventions.
The
administration
medications,
whether
oral,
injectable,
or
topical,
associated
range
side
effects
compliance
issues.
Topical
despite
their
advantages
in
patient
reduced
systemic
effects,
hindered
by
altered
skin
barrier
psoriasis,
which
impedes
effective
drug
penetration
retention.
In
recent
years,
development
novel
transdermal
delivery
systems
promising
frontier
management.
Nanotechnology-,
microneedle-
dressing-based
have
demonstrated
potential
for
improved
penetration,
enhanced
bioavailability,
extended
retention
time.
Here,
we
will
focus
on
latest
insights
into
etiology,
diagnostic
methodologies,
approaches
particular
emphasis
evolution
challenges
systems.
Язык: Английский
Outline of Therapeutic Potential of Different Plants Reported Against Psoriasis via In Vitro, Pre‐Clinical or Clinical Studies
Phytotherapy Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 4, 2025
ABSTRACT
Psoriasis
is
a
noncontagious,
autoimmune
chronic
inflammatory
disease
with
an
unknown
root
cause.
It
classified
as
multifactorial
and
skin
disorder
that
also
affects
the
immune
system
genetic.
Environmental
factors
such
stress,
infections,
injuries
all
play
important
role
in
disease's
development.
Although
there
no
cure
for
this
disease,
topical,
oral,
systemic
whole‐body
treatments
are
available
to
relieve
symptoms.
Several
plants
phytochemicals
which
have
been
found
effective
management
of
psoriasis
experimentally
(preclinical
clinical).
These
plants/phytochemicals
applications
treatments.
Traditionally,
some
utilized
primary
treatment,
including
their
extracts
and/or
phytochemicals,
individuals
moderate
severe
(due
fewer
side
effects),
while
phototherapy
generally
reserved
more
advanced
cases.
This
report
describes
various
be
against
vitro,
preclinical,
clinical
studies.
review
summarizes
key
findings
from
experimental
studies
on
pathological
aspects
may
useful,
effective,
informative
future
research.
Язык: Английский
Clinical application of biological agents in rheumatoid arthritis
Transplant Immunology,
Год журнала:
2025,
Номер
unknown, С. 102187 - 102187
Опубликована: Янв. 1, 2025
Язык: Английский
Pharmacotherapy of arterial hypertension in patients with psoriasis
Journal of Hypertension,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 18, 2025
Psoriasis
is
a
chronic
systemic
autoimmune
disease
associated
with
an
elevated
risk
of
developing
cardiovascular
disease.
In
patients
psoriasis,
arterial
hypertension
treatment
requires
careful
selection
antihypertensive
drugs,
as
some
drugs
may
worsen
the
skin
manifestations
psoriasis.
this
review,
we
summarize
available
evidence
regarding
risks
and
benefits
each
group
drugs.
We
also
suggest
scheme
for
optimizing
in
emphasis
on
achieving
effective
control
blood
pressure
disease,
while
minimizing
worsening
cutaneous
manifestations.
Angiotensin
receptor
blockers
appear
to
be
most
appropriate
hypertensive
potential
addition
calcium
channel
if
not
adequately
controlled.
Alternatives
are
angiotensin-converting
enzyme
inhibitors
and/or
mineralocorticoid
antagonists.
Diuretics
beta
greater
psoriatic
lesions.
Язык: Английский
Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model
Shuangshuang Xiong,
Jiaqi Yang,
Ming Yang
и другие.
Journal of Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 21, 2025
Tyrosine
kinase
2
(TYK2),
a
critical
scaffolding
required
for
type
I
interferon,
IL-12
and
IL-23
cytokine
signaling,
represents
compelling
therapeutic
target
various
autoimmune
diseases.
However,
existing
TYK2
inhibitors
only
modulate
its
activity.
Here,
we
report
the
development
of
first
series
CRBN-recruiting
PROTACs
based
on
an
allosteric
inhibitor.
Optimization
potency
metabolic
stability
identified
15t
as
exceptionally
potent
selective
degrader
with
DC50
value
0.42
nM
Dmax
95%,
which
potently
selectively
blocked
TYK2-dependent
signaling.
Importantly,
was
active
in
vivo
significantly
suppressed
TYK2-mediated
pathology
murine
psoriasis
model
without
apparent
toxicity.
Collectively,
our
study
provides
potentially
valuable
chemical
knockdown
probe
subtype-selective
degradation
further
understanding
biology,
demonstrating
potential
immuno-inflammatory
diseases
such
psoriasis.
Язык: Английский
Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Experimental Dermatology,
Год журнала:
2025,
Номер
34(4)
Опубликована: Апрель 1, 2025
ABSTRACT
JAK
inhibitors
are
used
to
treat
various
inflammatory
skin
diseases.
However,
systemic
formulations
associated
with
an
increased
risk
of
major
adverse
events.
Ruxolitinib
1.5%
cream
is
a
selective
topical
JAK1
and
JAK2
inhibitor,
which
has
recently
been
approved
by
EMA
MHRA
for
treating
non‐segmental
vitiligo,
while
being
FDA‐approved
both
vitiligo
atopic
dermatitis.
Recent
literature
reported
the
off‐label
use
several
conditions,
but
data
mostly
limited
single
case
reports
series
few
prospective
studies,
mixed
results.
We
conducted
systematic
review
investigate
potential
efficacy
in
diseases
setting.
The
following
keywords
were
searching
MEDLINE
(Pubmed)
Scopus
databases
from
inception
September
2024:
“ruxolitinib
dermatology”
“topical
ruxolitinib
dermatology”.
Reviews,
articles
not
focusing
on
main
topic,
books
book
chapters,
no
English
text
excluded.
A
total
170
studies
screened,
112
fell
within
exclusion
criteria
58
assessed
eligibility.
Of
these,
28
published
between
2012
2024,
selected.
resulted
lichenoid
granulomatous
dermatoses,
as
well
alopecia
areata.
While
former
proved
be
effective
safe,
results
areata
controversial.
Topical
might
promising
therapeutic
option
dermatoses.
Noteworthily,
despite
exciting
oral
formulation,
consistent
described
Our
encouraging
many
conditions
that
should
investigated
further
studies.
Язык: Английский
Decoy oligodeoxynucleotides targeting STATs in non-cancer gene therapy
Gene,
Год журнала:
2025,
Номер
unknown, С. 149482 - 149482
Опубликована: Апрель 1, 2025
Язык: Английский
Association between Life’s Essential 8 and psoriasis in US adults: a cross-sectional study
Frontiers in Medicine,
Год журнала:
2024,
Номер
11
Опубликована: Окт. 10, 2024
Psoriasis
is
closely
associated
with
cardiovascular
disease
(CVD).
However,
the
current
evidence
on
correlation
between
Life's
Essential
8
and
insufficient.
Our
aim
was
to
investigate
relationship
(LE8),
a
measure
of
health
(CVH),
psoriasis.
Язык: Английский
Study on the Mechanism of Compound Zeqi Granule in Treating Psoriasis vulgaris Based on Network Pharmacology and Experimental Verification
Natural Product Communications,
Год журнала:
2024,
Номер
19(11)
Опубликована: Ноя. 1, 2024
Background
This
study
used
a
holistic
network
pharmacological
approach
to
clarify
the
mechanism
of
Compound
Zeqi
Granule
(CZG)
in
treating
psoriasis
vulgaris
(PV).
Methods
The
potential
bioactive
compounds
and
corresponding
targets
CZG
were
collected
searched
via
TCMSP
database.
Disease
PV
obtained
from
GeneCards
standardized
by
UniProt
GO
KEGG
enrichment
analyses
performed
using
Metascape
Then,
molecular
docking
verification
was
conducted
CB-Dock
Animal
experiments
validate
effects
on
PV.
Results
identified
99
compounds,
579
drug
targets,
822
PV-related
108
target
proteins.
biological
processes
primarily
related
regulation
defense
response,
inflammatory
responses,
cellular
response
lipid.
for
significantly
associated
with
20
pathways
including
JAK-STAT
signaling
pathway.
confirmed
that
exerted
its
therapeutic
promoting
expression
IL-10
JUN,
inhibiting
activation
STAT1
STAT3.
Conclusion
present
provides
evidence
supporting
efficacy
treatment
through
multi-compound,
multi-target
multi-pathway
lays
theoretical
foundation
further
experimental
research
this
field.
Язык: Английский
A Case Series Report on the Effect of Tofacitinib on Joint Inflammation and Gut Microbiota Composition in Psoriatic Arthritis Patients Naive to Biologic Agents
Microorganisms,
Год журнала:
2024,
Номер
12(12), С. 2387 - 2387
Опубликована: Ноя. 21, 2024
Introduction:
Psoriatic
arthritis
(PsA)
is
a
complex
condition
within
the
Spondyloarthritis
(SpA)
group.
Recent
studies
have
focused
on
important
role
of
intestinal
microbiota
in
maintaining
immunological
homeostasis,
highlighting
how
dysbiosis
may
act
as
trigger
for
autoimmune
diseases.
Tofacitinib
Janus
kinase
inhibitor
(JAK-i)
with
proven
efficacy
treatment
both
rheumatoid
and
PsA.
However,
there
lack
data
its
ability
to
reduce
joint
remission
through
ultrasonography
(US)
effects
it
might
composition
gut
microbiota.
Methods:
Here,
we
present
case
series
seven
bio-naïve
PsA
patients
who
received
tofacitinib
were
followed
up
12
months.
The
clinical
response
was
assessed
using
validated
scores
(DAPSA,
ASDAS,
BASDAI),
laboratory
tests,
US
assessment
target
enthesis.
Finally,
evaluated
changes
next-generation
sequencing
analysis
fecal
samples.
Results:
study
showed
significant
improvement
all
used;
this
also
confirmed
by
reduction
synovitis
scores.
suggested
that
effectiveness
ameliorating
activity
associated
relevant
modification
some
bacterial
lineages.
No
cases
severe
adverse
reported.
Conclusions:
Treatment
proved
be
effective,
safe
capable
varying
selecting
strains
considered
beneficial
immune
modulation.
Язык: Английский